CE3F4

Key Product Details

Product Description

CE3F4 is a noncompetitive Epac1 inhibitor. Blocks Epac-induced Rap activation and prevents isoprenaline-induced autophagy flux in cardiomyocytes. Has no effect on PKA activity in the presence of cAMP.

Product Specifications for CE3F4

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for CE3F4

The following data is based on the product molecular weight 351.01.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.85 mL	14.24 mL	28.49 mL
5 mM	0.57 mL	2.85 mL	5.70 mL
10 mM	0.28 mL	1.42 mL	2.85 mL
50 mM	0.06 mL	0.28 mL	0.57 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 26 publications citing the usage of this product.

• Courilleau Identification of a tetrahydroquinoline analog as a pharmacological inhibitor of the cAMP-binding protein Epac. J.Biol.Chem. 2012 PMID: 23139415
• Chen The peripheral Epac1/p-Cav-1 pathway underlies the disruption of the vascular endothelial barrier following skin/muscle incision and retraction-induced chronic postsurgical pain. Ann.Transl.Med.
• Laurent Exchange protein directly activated by cAMP 1 promotes autophagy during cardiomyocyte hypertrophy. Cardiovasc.Res. 2015 PMID: 25411381

Product Documents for CE3F4